NCT06817343View on ClinicalTrials.gov

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2029

Conditions
Neovascular Age-Related Macular Degeneration (nAMD)Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions
BIOLOGICAL

Aflibercept (2.0 mg)

PRN IVT Aflibercept

Trial Locations (2)

16507

Erie Retina Research, Erie

89502

Sierra Eye Associates, Reno

Sponsors

Lead Sponsor

Exegenesis Bio
All Listed Sponsors
lead

Exegenesis Bio

INDUSTRY

NCT06817343 - A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU) | Biotech Hunter | Biotech Hunter